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NeuroﬁbromatosistypeIisacommontumorpredisposingdiseaseinhumans.Surgicaltherapycanbeappliedonlyinselectedpatients
withresectablemasses.Hence,developmentofnewtherapiesforthisdiseaseisurgent.Weusedhumanneuroﬁbromaimplantsinmice
withseverecombinedimmunodeﬁciency(SCID)asamodeltotestthetoxicityandpotentialeﬃcacyofpirfenidone,anewtherapeutic
agent. Two hundred twelve human neuroﬁbromas were transplanted into various locations in 59 experimental animals, and 30 mice
with implants received oral pirfenidone for up to six weeks. Survival of neuroﬁbromas in animals treated with pirfenidone was lower
than in the control group (P = .02). Tumors did not change histologic appearance or vascularization in response to pirfenidone.
Treatment with pirfenidone, a new antiﬁbrotic agent, inhibits survival of some tumors without causing toxicity in animals.
INTRODUCTION
NeuroﬁbromatosistypeI(NF1)isanautosomaldom-
inant condition aﬀecting about 1 in 3000 individuals.
The disorder shows extraordinary variability in clinical
presentation but most frequently causes benign neural
tumors, neuroﬁbromas, and abnormal pigmentation in
form of cafe-au-lait macules, intertriginous freckling of
skin, and Lisch nodules of the iris. The diagnosis of NF1
is based on clinical criteria, as deﬁned at an NIH Consen-
sus Development Conference [1]. Individuals with NF1
are at risk for optic nerve gliomas, nerve root and plexi-
form neuroﬁbromas, schwannomas, spinal cord tumors,
benign and malignant peripheral nerve sheath tumors,
and pheochromocytomas [2, 3]. Plexiform neuroﬁbro-
mas tend to inﬁltrate the surrounding tissues causing dis-
ﬁgurement and compromise of nearby vital structures by
compression. These tumors may be multiple and may
show rapid growth throughout life, but the periods of
greatestriskarepubertyandchildbearingage.Surgicalre-
moval of peripheral nerve tumors still remains the only
therapeutic option; however, in many patients, tumors
cannot be completely resected, and there is a high rate
of regrowth (about 50%), especially in young children af-
ter resection of tumors of the head/neck/face [4]. There-
fore, new approaches to therapy that would arrest pro-
gressive course of NF1 are urgently needed [5]. One hur-
dle to developing new therapies for NF1 has been the lack
of a suitable animal model. Attempts of implantation of
human neuroﬁbroma in experimental animals were made
before [6, 7, 8], but not in the subcutaneous location of
a mouse ear, which has an advantage of easy accessibil-
ity of the tumor for monitoring the survival, growth, or
changes in vascularization. We have developed a model in
which fragments of human neuroﬁbroma are implanted
in various locations in immunodeﬁcient mice and used
the model for initial testing of an agent that might be use-
ful in therapy of neuroﬁbromatosis.
The agent we explored was pirfenidone, 5-methyl-1-
phenyl-2-(1H)-pyridone, a novel antiﬁbrotic drug that
has been shown to inhibit ﬁbroblast growth and colla-
gen synthesis. Pirfenidone modulates the action of such
cytokines, as platelet-derived growth factor, ﬁbroblast
growth factor, epidermal growth factor, intercellular ad-
hesion molecule-1 [9], and transforming growth factor
beta-1 [10]. Inhibition of these cytokines decreases pro-
liferation and collagen matrix synthesis by human ﬁ-
broblasts. Antiﬁbrotic eﬀects of pirfenidone have been
reported in animals, suggesting therapeutic potential in
many ﬁbrosing conditions [11, 12]. The histopathology
of neuroﬁbromas is characterized by slender spindle cells
with an abundant extracellular matrix of dense, wavy col-
lagen ﬁbers and extracellular mucoid material. Up to 70
percent of the tumor dry weight is collagen [13, 14]. Al-
though the understanding of molecular events that lead
to the development of neuroﬁbromas in NF1 is still in-
complete, comparison of the eﬀects of pirfenidone with
the observed alterations in NF1 led to our hypothesis that80 Dusica Babovic-Vuksanovic et al 2004:2 (2004)
pirfenidone might exert a therapeutic eﬀect in NF1, by
targeting ﬁbrotic component of these tumors. We tested
the toxicity of pirfenidone and evaluated eﬃcacy of short
course of therapy as a prelude to clinical trials.
MATERIALS AND METHODS
Animals
Mice with severe combined immunodeﬁciency
(SCID) were used as recipients of human neuroﬁbroma
xenotransplants. SCID mice have a deﬁciency in the
DNA-dependent protein kinase (DNA-PK), which results
in ineﬃcient recombination of DNA ends generated
during the course of antigen receptor recombination
[15]. This defect blocks lymphopoiesis at early stages of
T- and B-cell development and prevents the mounting of
immune responses against the grafts.
Two hundred twelve human neuroﬁbromas were
transplantedintovariouslocationsin59experimentalan-
imals, 30 in the epineurium of the sciatic nerve, and 182
undertheskinoftheneck,back,andskinoftheear.Thirty
mice with implants received oral pirfenidone for up to six
weeks, and 29 animals were monitored for survival of tu-
mors without therapy.
Humanneuroﬁbromas
Human neuroﬁbromas were obtained from four pa-
tients with neuroﬁbromatosis who underwent removal
of plexiform neuroﬁbroma due to pain, compression, or
other clinical indications. One tumor was described as a
nodular plexiform neuroﬁbroma, while the other 3 had
appearanceofdiﬀuseplexiformneuroﬁbroma.Tumortis-
sue that would normally be discarded was used for these
experiments. Each tumor was initially evaluated by frozen
section histology, and if conﬁrmed to be a neuroﬁbroma,
tumor tissue was prepared for implantation. The size of
the tumors ranged from 2cm to 4cm at the greatest di-
ameter. The tissue was placed into sterile culture medium
with an antibiotic and cut into 2 × 2 × 2mm(1–2mil-
ligrams) pieces. Two hundred and twelve tumor frag-
ments were obtained by cutting neuroﬁbromas originat-
ing from four diﬀerent patients. Tumors were weighed
and measured by a caliper (two largest perpendicular di-
ameters) before implantation. Part of the tumor was eval-
uated by histology as described below.
Surgicalprocedure
Surgicalprocedureswereconductedundersterilecon-
ditions. Eachmousewasanesthetized using5%halothane
inhalation followed by 1%–2% halothane for mainte-
nance. Tumor fragments were implanted subcutaneously
in the area of back, neck, and on the posterior surface
of the ear. Prior to incision, the skin was thoroughly
cleaned with 70% ethanol and Betadine solution. Inci-
sions were performed longitudinally oriented on the skin
of designated areas. The implantation pockets were dis-
sected with microscissors. Care was taken to minimize
mechanical trauma to the graft. After implantation of the
tumor grafts, skin was closed with resorbable (Chromic
catgut 5/0) suture. We used method previously described
by Lee et al for implantation of neuroﬁbroma fragment
into the epineurium of the sciatic nerve [16]. Tumor im-
plants were secured with a Prolene 8/0 surgical suture.
Pirfenidonetherapy
Tumors were implanted in four diﬀerent occasions,
depending on availability of the human donor. After the
implantationofxenograftsfromeachdonor,animalswere
randomized into two groups. Thirty SCID mice with im-
planted tumor fragments in various body locations were
treated with oral pirfenidone (at a dose of 500mg/kg per
day). Therapy was initiated the second day after tumor
implantation. The remaining 29 untreated mice with im-
plants from the same tumors were used as controls.
Assessmentoftumorgrowth
The animals with tumor implants in the epineurium
and under the skin of neck and back were followed for
up to six weeks. The survival and size of tumor implants
in subcutaneous locations were assessed by external pal-
pation through the skin of the neck and back and mea-
surement of the perpendicular diameters prior to tumor
removal.
Animals were sacriﬁced 2, 3, 4, 5, and 6 weeks after
tumor implantation. Neuroﬁbroma implants were recov-
ered, weighed, and measured for the largest surface area.
Tumor tissue was prepared for routine histology and im-
munostaining. The authors were masked to a treatment
status of animals at the time of tumor measurement to
minimize bias.
Two animals with tumor implants under the skin of
ear were followed for twelve months without therapy.
Tumor appearance and size of tumors were assessed by
inspection and direct outside measurement of the two
largest perpendicular diameters and calculation of area,
using acaliperwith 0.025mm accuracy(Skilltech,Hempe
Manufacturing Co, Inc, New Berlin, Wis) (Figure 1a).
Measurements were performed two weeks after implan-
tation and then monthly thereafter.
Histologyandimmunohistochemistry
Tumor specimens were ﬁxed in 10% neutral buﬀered
formalin, pH = 7.2 ,f o ru pt o1 8h o u r sa tr o o mt e m -
p e r a t u r e( R T ) ,t h e ne m b e d d e di np a r a ﬃn using a tis-
sue processor (model PTP 1530, Ventana Medical Sys-
tems, Tucson, Ariz). Sections prepared from these blocks
were placed on positively charged microscope slides (Su-
perfrost Plus, Fisher Scientiﬁc, Pittsburgh, Pa). The sec-
tions were then deparaﬃnized with xylene and rehy-
drated using graded ethanol solutions. For immunohisto-
chemical methods, endogenous peroxidase was quenched
by incubation of the sections with 1.5% H2O2 in 50%
methanol.2004:2 (2004) Pirfenidone in NF1 81
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Figure 1. (a) Viability of human neuroﬁbroma xenograft in
SCID mouse ear for 12 months after implantation, without
therapy with pirfenidone. Human neuroﬁbromas conﬁrmed by
frozen section histology were cut in 2 × 2mm pieces and im-
planted subcutaneously into the ear of SCID mice. Tumor size
was assessed by inspection and direct outside measurement of
thetwolargestperpendiculardiametersandareacalculation,us-
ing a caliper with 0.025mm accuracy. (b) Neuroﬁbroma xeno-
transplants in the ear were stable in size for twelve months after
implantation. The line shows an average size of four tumor im-
plants in the ears, based on area calculation.
Human S-100 A and B protein was detected using
rabbit antiserum (Dako Corp, Carpinteria, Calif) diluted
with phosphate-buﬀered saline (PBS), pH = 7.2, con-
taining 5% bovine serum albumin (BSA), and applied to
sections. The rabbit anti-S-100 antibodies were detected
using aﬃnity puriﬁed biotinylated F(ab )2 swine anti-
rabbit IgG (Dako), followed by horseradish peroxidase-
conjugated streptavidin (Dako), both diluted in 5%
PBS/BSA. Specimens were counterstained with alum-
hematoxylin solution, dehydrated using graded ethanols,
cleared in xylene, and coverslipped with a synthetic
mounting medium.
Binding of Griﬀonia Simplicifolia (GS) lectin I,
isolectin B4 (IB4), a lectin which binds to Galα1-3Gal
in porcine tissues, was tested in tissue sections prepared
as described above [17] .T h es e c t i o n sw e r et r e a t e dw i t h
a microwave-assisted carbohydrate revealing (MCR) by
incubating them with 75mL of 10mM citric acid, pH =
6.0, and subjecting them to microwave athigh power (800
watt, Panasonic, Secaucus, NJ) inside a beaker contain-
ing 400mL distilled water up to 15 minutes. The vol-
ume was maintained at a constant level during heating by
the addition of distilled water as required. Sections were
then incubated for 15 minutes at RT within the residual
solution prior to application of the lectin. Fluorescein-
conjugated IB4 (Vector Laboratories, Burlingame, Calif)
diluted in PBS, pH = 7.2, containing 5% BSA, was ap-
plied to the sections at RT for one hour and then rinsed
with PBS. Slides were then coverslipped with a 1 : 8 di-
lution of Vectashield-DAPI (1.5µg/mL 4,6-diamidino-2-
phenylindole, Vector Laboratories) in PBS, pH = 8.6, and
stored in the dark at 4◦C. Sections from formalin-ﬁxed,
paraﬃn-embedded tissues were also stained with hema-
toxylin and eosin (H&E) and Masson’s Trichrome [18].
Slides were examined using a brightﬁeld or epiﬂuorescent
microscope, and digital photomicrographs were obtained
utilizing a high-resolution CCD digital camera (SPOT II,
DiagnosticInstruments,SterlingHeights,Mich)mounted
tothemicroscope(LeicaDMRD,LeicaMicrosystems,Inc,
Bannockburn, Ill) and SPOT II software.
Statisticalmethods
The frequency of surviving tumors was tabulated and
compared using the Chi-square test.
RESULTS
Fateofhumanneuroﬁbromaxenografts
withouttreatment
One hundred-six fragments of human neuroﬁbromas
were implanted in various locations in 29 SCID mice, and
werefollowedforsurvivaloftumorgraftswithouttherapy
for up to six weeks. Two mice with implants under the
skin of ear were monitored for twelve months.
The survival of the neuroﬁbroma xenografts in the
various locations ranged from 84.6% to 100% (Table 1).
Implants which did not survive could not be found or
could not be identiﬁed as neuroﬁbromas by inspection.
The tissue retrieved in some of these locations appeared
pale, soft, and transparent; microscopic evaluation of
thesesamplesfailedtoshowcharacteristicfeaturesofneu-
rogenic tumors. Subcutaneously implanted tumors had
similar survival rates (77/91) as tumors implanted into
epineurium of the sciatic nerve (13/15) (P = .37). Sur-
vival of tumors implanted in the neck and back was sim-
ilar (P = .41). Implanted tumors showed no aggressive
propertiesortissueinvasionandmaintainedthesamesize
overthesixweeksofthefollowup,asdocumentedbymea-
surement of tumor mass and volume (data not shown).
Neuroﬁbroma xenotransplants in the ear were stable in
appearance and size for twelve months postimplantation
(Figure 1b).82 Dusica Babovic-Vuksanovic et al 2004:2 (2004)
Table 1. Survival of human neuroﬁbroma xenografts in diﬀerent locations of SCID mice, without therapy.
Tumor location 2 weeks 3 weeks 4 weeks 5 weeks 6 weeks 12 months Total
Sciatic nerve 1/2 2/2 2/3 3/3 5/5 — 13/15 (86.7%)
Subcutaneous 16/17 14/17 13/15 13/15 17/23 4/4 77/91 (84.6%)
Neck 9/9 7/9 7/8 7/8 11/12 — 41/46 (89.2%)
Back 7/8 7/8 6/7 6/7 7/11 — 33/41 (80.1%)
Ear — — — — — 4/4 4/4 (100%)
Total 90/106 (84.9%)
Table 2. Eﬀect of treatment with pirfenidone for six weeks on survival of human neuroﬁbroma in SCID mice.
Survival of xenotransplant  Pirfenidone therapy
P
Treated Not treated∗
All neuroﬁbromas 76/106 (71.7%) 86/102 (84.3%) 0.0215
Sciatic nerve 9/15 (60.0%) 13/15 (86.7%) 0.1077
Subcutaneous 67/91 (73.6%) 73/87 (83.9%) 0.1361
  Survival of implants was determined by positive histologic identiﬁcation of neuroﬁbroma. “Failed” implants were deﬁned as an absent tumor or an
atypical appearance of retrieved implant without histologic characteristics of neurogenic tumors.
∗ Four additional tumors implanted in the ear and followed up for 12 months without treatment are not included in this table.
Histologicandimmunohistochemical
propertiesoftumors
Overthe6weeksofmonitoring,humanneuroﬁbroma
implants retained the histologic characteristics of the
original tumors. The presence of collagen within the tu-
mor specimens was conﬁrmed using Masson’s trichrome
stain (Figure 2). No signiﬁcant change in cellularity or
collagen content was observed, except that tumors ap-
peared more dense in 6-week-old implants (Figures 2 and
3). The immunohistochemical reaction with anti-S-100
remained as strong as in the original tumor (Figure 3).
Vascularization of tumors appeared fully established by
histology within seven days and was not changed over six
weeks of followup. The blood vessels were of host origin
since they bound GS IB4, a lectin recognizing Galα1-3Gal
on cells of nonprimates (Figure 4).
Tumors implanted subcutaneously and in the nerve
epineurium exhibited minimal histologic diﬀerences.
Some tumors implanted into nerve epineurium had acute
inﬂammation and some had a granulomatous reaction
consisting of histiocytes and multinucleated giant cells in
proximity to sutures. Tumors in subcutaneous locations
did not have signs of inﬂammatory response.
EFFECTS OF PIRFENIDONE
Toxicity and short-term eﬀects of pirfenidone, a novel
antiﬁbrotic drug, were explored as a new therapy for NF1.
No increased mortality or signs of drug toxicity was ob-
served in animals treated with pirfenidone. Survival of
neuroﬁbromas in animals treated with pirfenidone was
lower than in control animals, irrespective of the loca-
tion of implanted tumor (Table 2). Tumor grafts derived
from four diﬀerent patients showed no diﬀerence in sur-
vival rate. Surviving tumors in treated animals did not
show histologic diﬀerences from tumors in untreated ani-
mals.Tumorsintreatedanimalswerevascularizedbyhost
blood vessels, similar to tumors in control animals.
DISCUSSION
Human neuroﬁbromas xenotransplanted into im-
munodeﬁcient mice oﬀer an attractive experimental
model which allows researchers to explore therapies for
NF1. Lee et al reported that human neuroﬁbromas trans-
planted in the sciatic nerve of nude mice grew for over 6
weeks after the implantation, and tumor enlargement and
stability correlated with vascularity [16]. The monitoring
of changes in tumors implanted in deep tissue, such as
subrenal capsule and sciatic nerve epineurium, required
surgical exploration of implanted tumors [16]. The as-
sessment of tumor implants in these locations is thus dif-
ﬁcult. Further, because deep implants must be secured by
sutures, inﬂammatory responses may ensue, making the
monitoring of outcome more diﬃcult. Here we show that
human tumors can be implanted in more approachable
locations, particularly the ear, where monitoring can be
conducted more easily.
The implantation of human tumor under the skin of
the ear has the advantage of easy accessibility of the tumor
for monitoring of survival, growth, or changes in vascu-
larization. Surgical implantation in this subcutaneous lo-
cation is rapid and technically straightforward and does
not produce substantial trauma nor detectable inﬂamma-
tory response to surrounding tissues. Our animal model
could be used for discovery of new therapies for NF12004:2 (2004) Pirfenidone in NF1 83
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Figure 2. Evaluation for content of collagen in human neu-
roﬁbroma xenografts in SCID mouse. Sections from formalin-
ﬁxed, paraﬃn-embedded tissues were stained with Masson’s
Trichrome and slides were examined using a brightﬁeld micro-
scope. Original tumor tissue (a) and the xenotransplant recov-
ered 6 weeks after implantation without therapy (b) or with pir-
fenidone treatment (c). Samples from the original tumor and 6-
week-old implants were stained with Trichrome suggesting the
presence of similar content of collagen. Tumors recovered from
animals treated with pirfenidone did not display diﬀerence in
Trichrome staining, suggesting that 6-week therapy did not in-
ﬂuence the content of collagen.
and might oﬀer an opportunity to study the response
of tumors from individuals to various combinations and
dosages of therapeutics, allowing customized therapy for
NF1.
(a)
(b)
(c)
Figure 3. Localization of S-100 in human neuroﬁbroma trans-
planted into SCID mouse. Tissue samples from original tumors
and from human neuroﬁbroma xenografts were snap-frozen,
cryo-sectioned, stained with rabbit antibodies speciﬁc for hu-
man S-100 and studied by immunoﬂuorescence microscopy.
Fluorescence is localized in Schwann cells in the original tumor
(a) and in tumor xenografts recovered 6 weeks after implan-
tation from nontreated animal (b) and from animal receiving
pirfenidone (c). The presence of S-100 in the xenografts con-
ﬁrms persistence of Schwann cells in implanted tumors. Positiv-
ity for S-100 was not changed by treatment with pirfenidone for
6w e e k s .
Neuroﬁbromas are benign tumors, with unpredict-
able pattern of progression. While they may enlarge in
early childhood, adolescence, and during the pregnancy,
at other times, their growth is mostly indolent. Contrary84 Dusica Babovic-Vuksanovic et al 2004:2 (2004)
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Figure 4. GS IB4 lectin binding in human neuroﬁbroma
implanted into SCID mouse. Sections from formalin-ﬁxed,
paraﬃn-embedded tissues from original tumors and from hu-
man neuroﬁbroma xenografts were incubated with ﬂuorescein-
conjugated IB4. Slides were examined using an epiﬂuorescent
microscope. Fluorescence indicates binding of lectin to Galα1-
3Gal on blood vessel cells of nonprimates. Original human
tumor (a) does not show ﬂuorescence. Human neuroﬁbroma
xenotransplant from nontreated animal (b) and human neu-
roﬁbroma xenotransplant from animal treated with pirfenidone
for 6 weeks (c) show ﬂuorescence suggesting that vessels were of
host origin since they bound GS IB4. The host origin of blood
vesselswasnotchanged inresponsetotherapywithpirfenidone.
to previous reports [16], we did not observe substantial
changes in tumor size after transplant except for modest
andtransientincreaseinsizeintheﬁrstweekpostimplan-
tation. These changes probably reﬂect tissue swelling as a
reaction to the surgical trauma. The lack of measurable
growth of tumors in our model did not allow us to eval-
uate if pirfenidone is capable of arresting tumor enlarge-
ment. However, the indolence of xenotransplants prob-
ably reﬂects the general behavior of the tumors in hu-
mans. Many factors have been postulated to play a role in
the pathogenesis of neuroﬁbromas, including hormones,
trauma, growth factors, and surgical manipulations, but a
fundamental understanding of events implicated in their
development and growth is lacking.
Finally, we have used our experimental model to test
the potential toxicity and eﬃcacy of pirfenidone, a new
antiﬁbrotic drug, in the treatment of plexiform neuroﬁ-
bromas. Pirfenidone showed no toxicity and reduced sur-
vival of neural tumors during the six weeks of study.
Our ﬁndings do not allow us to suggest by which mech-
anism(s) pirfenidone inhibits tumor survival. Since the
beneﬁt we observed might increase over longer periods
of time, additional studies are necessary to evaluate the
eﬀects of prolonged therapy with pirfenidone. However,
our results indicate that pirfenidone is a good candidate
for therapy of neuroﬁbromatosis type I and therefore fur-
ther investigations are warranted to determine the mech-
anism of action and long-term eﬀects of treatment with
this agent.
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